Cart
sales@molnova.com
(3aR)-Selitrectinib
CAS No. 1350884-56-8
(3aR)-Selitrectinib( BAY 2731954 | (6RS)-LOXO-195 )
Catalog No. M28716 CAS No. 1350884-56-8
(6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | Get Quote |
|
| 5MG | 72 | Get Quote |
|
| 10MG | 110 | Get Quote |
|
| 25MG | 215 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name(3aR)-Selitrectinib
-
NoteResearch use only, not for human use.
-
Brief Description(6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
-
Description(6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsBAY 2731954 | (6RS)-LOXO-195
-
PathwayTyrosine Kinase
-
TargetTrk Receptor
-
RecptorApoptosis|MARK3|MARK4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1350884-56-8
-
Formula Weight380.427
-
Molecular FormulaC20H21FN6O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[H][C@]12CCCN1c1ccn3ncc(C(=O)NC(C)CCc4ncc(F)cc24)c3n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Fangfang Li, et al. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression?in vitro?and?in vivo. Acta Pharm Sin B.2020 Feb;10(2):289-300.
molnova catalog
related products
-
LM11A-31
An orally available, brain penetrant p75NTR ligand that blocks p75-mediated cell death, also increases proliferation and survival of hippocampal neural progenitors.
-
(3aR)-Selitrectinib
(6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
-
Entrectinib
Entrectinib (NMS-E628, RXDX-101, NMS-01191372) is a potent, ATP-competitive, orally available pan-TRK, ROS1 and ALK inhibitor with IC50 of 1/3/5/12/7 nM for TRKA/TRKB/TRKC/ALK/ROS1, respectively.
